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Abstract
Changing to burosumab, a monoclonal antibody targeting fibroblast growth factor 23, significantly improved phosphorus 
homeostasis, rickets, lower-extremity deformities, mobility, and growth versus continuing oral phosphate and active vita-
min D (conventional therapy) in a randomized, open-label, phase 3 trial involving children aged 1–12 years with X-linked 
hypophosphatemia. Patients were randomized (1:1) to subcutaneous burosumab or to continue conventional therapy. We 
present patient-reported outcomes (PROs) from this trial for children aged ≥ 5 years at screening (n = 35), using a Patient-
Reported Outcomes Measurement Information System (PROMIS) questionnaire and SF-10 Health Survey for Children. 
PROMIS pain interference, physical function mobility, and fatigue scores improved from baseline with burosumab at weeks 
40 and 64, but changed little with continued conventional therapy. Pain interference scores differed significantly between 
groups at week 40 (− 5.02, 95% CI − 9.29 to − 0.75; p = 0.0212) but not at week 64. Between-group differences were not 
significant at either week for physical function mobility or fatigue. Reductions in PROMIS pain interference and fatigue 
scores from baseline were clinically meaningful with burosumab at weeks 40 and 64 but not with conventional therapy. 
SF-10 physical health scores (PHS-10) improved significantly with burosumab at week 40 (least-squares mean [standard 
error] + 5.98 [1.79]; p = 0.0008) and week 64 (+ 5.93 [1.88]; p = 0.0016) but not with conventional therapy (between-treatment 
differences were nonsignificant). In conclusion, changing to burosumab improved PRO measures, with statistically significant 
differences in PROMIS pain interference at week 40 versus continuing with conventional therapy and in PHS-10 at weeks 
40 and 64 versus baseline.
Trial registration: ClinicalTrials.gov NCT02915705
Keywords Burosumab · X-linked hypophosphatemia · Patient-reported outcomes · Patient-reported outcomes measurement 
information system
Introduction
X-linked hypophosphatemia (XLH) is a rare, heritable, life-
long phosphate-wasting disease. Loss-of-function mutations 
in the PHEX (phosphate-regulating endopeptidase homo-
logue, X-linked) gene result in characteristic elevation of 
circulating fibroblast growth factor 23 (FGF23) levels, lead-
ing to reduced renal phosphate reabsorption and decreased 
production of active vitamin D (1,25[OH]2D) manifesting as 
chronic hypophosphatemia and impaired mineralization of 
bones and teeth, as well as muscle weakness [1, 2].
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XLH typically manifests in early childhood as rickets, 
skeletal deformities, short stature, and in some children with 
dental abscesses [1–4]. Untreated or inadequately treated 
children commonly suffer impaired mobility and physical 
function, such as delayed walking, unusual gait, muscle 
weakness, bone, joint, and muscle pain, and emotional and 
social challenges [2–4]. Short stature acquired in childhood 
and skeletal deformities are irreversible, without surgery, 
after completion of growth. Elevated circulating FGF23 
and hypophosphatemia persist into adulthood; adults often 
develop pseudofractures, fractures, enthesopathies, hyper-
parathyroidism, and early-onset osteoarthritis, and suffer 
increasing pain, stiffness, and loss of physical function [3].
For the past 40 years, therapy for XLH has primarily 
consisted of multiple daily doses of oral phosphate supple-
mentation with active vitamin D (calcitriol or alfacalcidol; 
“conventional therapy”). Oral phosphate preparations can be 
unpalatable and can cause gastrointestinal symptoms, and 
the frequent dosing regimen is burdensome for patients and 
their caregivers [2, 3, 5]. Furthermore, regular monitoring 
and appropriate dose adjustments are needed to minimize 
the risk of complications of conventional therapy including 
nephrocalcinosis and hyperparathyroidism [1–3, 5].
Burosumab is a fully human monoclonal antibody (IgG1) 
that binds to FGF23 and inhibits its activity [6, 7]. The effi-
cacy of burosumab in pediatric XLH has been demonstrated 
by increasing the levels of serum phosphorus in two phase 
2 studies (UX023-CL201, NCT02163577; UX023-CL205, 
NCT02750618), as well as in children with rickets (rick-
ets severity score [RSS] ≥ 2.0) in the randomized phase 3 
trial of burosumab versus continued conventional therapy 
(UX023-CL301, NCT02915705). These trials demonstrated 
improvement in clinical outcomes, including rickets, lower-
limb deformities, and mobility, as assessed by the 6-min 
walk test, with the CL301 trial demonstrating superiority of 
changing to burosumab over continuation of conventional 
therapy [2, 8, 9].
In addition to clinical outcomes, patient-reported out-
come (PRO) data were collected in the phase 3 pediatric trial 
using Patient-Reported Outcomes Measurement Information 
System (PROMIS) instruments, the Short Form-10 (SF-10) 
Health Survey for Children, and the Faces Pain Scale—
Revised (FPS-R) to quantify the impairment and compare 
their evolution on burosumab versus continued conventional 
therapy. Pain is prevalent in pediatric patients with XLH 
and is most frequently observed in the lower limbs, but also 
occurs in the back and hips [4]. Children with XLH often 
have trouble performing age-appropriate gross motor activi-
ties, such as walking, running, and jumping, due to bowing 
of the femur, tibia, and fibula, and tibial rotation that causes 
the feet to turn in towards each other. Gait disturbance is 
common in pediatric patients with XLH, reported in > 80% 
of children [4].
Here, we present the PRO results from the phase 3 pediat-
ric trial, specifically the endpoints of PROMIS pain interfer-
ence, physical function mobility, and fatigue; health-related 
quality of life (HRQoL) according to SF-10; and pain inten-
sity according to FPS-R. We also conducted a subgroup 
analysis to investigate whether PRO scores varied with 
rickets severity, sex, geographic region, or PHEX disease-
causing variant.
Subjects and Methods
This open-label, randomized, active-controlled, phase 3 
trial was conducted at 16 international sites with experience 
treating XLH. The institutional review board at each partici-
pating center approved the protocol. The trial was conducted 
in accordance with the Declaration of Helsinki and the Good 
Clinical Practice guidelines developed at the International 
Conference on Harmonization of Technical Requirements 
for Registration of Pharmaceuticals for Human Use. Trial 
design details have been published previously [9] and are 
only briefly described here.
Eligibility criteria for this trial were as follows: age 
1–12 years when informed consent was obtained; confirmed 
diagnosis of XLH according to fasting serum phospho-
rus < 0.97 mmol/L (3.0 mg/dL); a confirmed PHEX disease-
causing variant or a variant of unknown significance in the 
patient, or in a directly related family member with appropri-
ate X-linked dominant inheritance; radiographic evidence of 
rickets in the wrist and/or knee; a total Thacher RSS ≥ 2.0; 
and prior treatment with conventional therapy for ≥ 6 con-
secutive months (children aged < 3 years) or ≥ 12 consecu-
tive months (children aged ≥ 3 years) up until enrollment. 
Parents or guardians provided written informed consent 
for their children to participate, and children gave written 
assent according to local guidelines. Patients were randomly 
assigned (1:1) to receive subcutaneous burosumab (starting 
dose 0.8 mg/kg every 2 weeks) or continue conventional 
therapy with oral phosphate and active vitamin D, the doses 
of which were titrated and individualized based on published 
recommendations [1, 6]. Patients received study medication 
for up to 64 weeks. PRO instruments were completed at 
baseline and at weeks 24, 40, and 64.
Patient‑Reported Outcome Assessments
PROs were assessed using linguistically validated, approved 
instruments during the trial for patients aged ≥ 5 years only 
at the screening visit. PROMIS is a set of measures devel-
oped by the US National Institutes of Health to evaluate 
physical, mental, and social health [10, 11]. A fixed-length 
short-form PROMIS instrument comprising the pain inter-
ference, physical function mobility, and fatigue domains 
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was created by selecting items from the three pediatric item 
banks of PROMIS (version 2.0; Online Resource, Table 2). 
Pain interference consisted of four items scored using five 
response options indicating the frequency of pain interfer-
ence (“never,” “almost never,” “sometimes,” “often,” and 
“almost always”); physical function mobility consisted of 10 
items scored using five response options to indicate sever-
ity (“with no trouble,” “with a little trouble,” “with some 
trouble,” “with a lot of trouble,” and “not able to do”); and 
fatigue consisted of eight items scored using five response 
options indicating the severity (“never,” “almost never,” 
“sometimes,” “often,” and “almost always”).
Items were selected using information from qualitative 
interviews of five children with XLH aged 8–12 years and 
their parents: one parent of an 8-year-old child with XLH 
and four parents of children with XLH aged 5–7 years. Item 
appropriateness was based on evidence from the concept 
elicitation, conceptual mapping, and cognitive debriefing 
exercises conducted as part of the qualitative interviews. 
The pain interference, physical function mobility, and 
fatigue items were well understood and found to be rel-
evant and appropriate assessments of those concepts for 
the children and their parents. These qualitative data there-
fore established content validity of the selected PROMIS 
domains. An analysis of the psychometric properties of the 
PROMIS instrument (both the self-reported form for chil-
dren aged ≥ 8 years and the parent proxy report form for 
children aged 5 to < 8 years) consisting of the three domains 
in the current trial (n = 35; children aged 5–12 years) con-
firmed it to be a reliable, valid, and responsive method for 
use in clinical trials in children with XLH [12].
The PROMIS domains were each measured at study 
assessment visits using a recall period of the previous 
7 days. Children aged ≥ 8 years at screening completed 
a self-reported PROMIS instrument. For children aged 5 
to < 8 years at screening, the parent or legal guardian com-
pleted the parent proxy version of the PROMIS instrument 
throughout the trial. PROMIS data were uploaded to the 
PROMIS online scoring system [13] to obtain the final 
scores for each domain. All raw scores generated from 
the PROMIS instrument were translated into standardized 
scores (termed T-scores), based on a calibration sample 
resulting in a calibration population mean of 50 and stand-
ard deviation (SD) of 10. The calibration sample consisted 
of a US cohort of 4,129 children aged 8–17 years, with 55% 
aged 8–12 years. The majority of children in the calibration 
sample (94%) were recruited from hospital-based general 
pediatric and subspecialty clinics, with 6% from school set-
tings; 35% had consulted a clinician for a chronic illness 
diagnosis or treatment within 6 months, and 9% had two 
or more chronic illnesses (the most common chronic con-
ditions were asthma, affecting 18% of children, followed 
by attention-deficit disorder/attention-deficit hyperactivity 
disorder [ADHD], arthritis, and gastrointestinal disorders) 
[14]. Higher scores on the PROMIS pain interference and 
fatigue domains indicate greater detriment (i.e., worse pain 
and more fatigue), whereas a higher score on the PROMIS 
physical function mobility domain indicates less detriment 
(i.e., better physical function mobility).
Overall HRQoL was assessed using the SF-10 Health 
Survey for Children, a validated 10-item, caregiver-com-
pleted questionnaire designed to assess physical and psy-
chosocial HRQoL in healthy and ill children. Each ques-
tion has five response options (“Excellent,” “Very good,” 
“Good,” “Fair,” and “Poor”) with a recall period of the past 
4 weeks. Responses were used to generate two component 
summary scores: physical health score (PHS-10) and psy-
chosocial health score (PSS-10), scored according to pub-
lished methods [15]. The scale was scored so that a score 
of 50 corresponds to the average score in a 2006 sample, 
which comprised a combination of children from the general 
population and a supplemental sample with disability and 
chronic conditions; higher global scores are associated with 
better HRQoL.
The FPS-R was used to assess current pain at each study 
visit. The self-reported scale uses graphical facial repre-
sentations of pain to allow self-reporting of current pain 
intensity at rest (not during or immediately after physical 
activity) on a 0–10 scale (0 = no hurt to 10 = hurts worst; 
even numbers only) and has been validated in children aged 
5–16 years [16].
Statistical Analysis
The primary endpoint for this trial, namely change in rickets 
severity from baseline to week 40, has been reported previ-
ously [9]. Changes from baseline in PROMIS scores were 
assessed as secondary endpoints, and changes from baseline 
in SF-10 PHS-10 and PSS-10 were assessed as exploratory 
endpoints. Here, we report data for changes to week 64 to 
provide longer-term information on XLH in children. SAS® 
software version 9.4 or higher (SAS Institute, Cary, NC, 
USA) was used for statistical analyses.
PRO endpoints were analyzed using a generalized esti-
mating equation repeated-measures analysis. Treatment, 
visit, and interaction of treatment-by-visit were included as 
categorical variables, and baseline measures and baseline 
total RSS stratification factor were included as independent 
variables in the model. Total RSS was used in this model, as 
it has been validated in 52 children with XLH, with higher 
total RSS associated with greater impairment in walking 
ability as assessed by the 6-min walk test [17]. Data for 
model-based estimates of the changes from baseline, stand-
ard error (SE), and corresponding 95% confidence intervals 
(CIs) were assessed for significance at the 5% level. Missing 
data were treated as missing for all analyses. Only data for 
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patients with a baseline measurement and at least one post-
baseline measurement were included in analyses of change 
from baseline.
As the trial was not powered to assess differences in 
between-group changes beyond the primary endpoint, 
within-group changes from baseline were reported for 
variables with nonsignificant between-group differences. A 
change of 2–3 points is considered clinically meaningful for 
PROMIS pediatric scales [18]. To interpret within-group 
trial results, clinically relevant differences were explored 
based on a minimally important difference (MID) threshold 
of 3 points [19].
In an exploratory analysis, testing for treatment-by-
subgroup was used to detect treatment effect heterogeneity 
across four subgroups (RSS: ≤ 2.5, > 2.5; sex: male, female; 
region: Japan, rest of world; PHEX status: clearly pathogenic 
PHEX variants, or likely pathogenic/variant of unknown sig-
nificance) on the PRO domains using week 40 and week 64 
data.
Results
PRO assessments were completed (by the child or their par-
ent/guardian) for all participants aged ≥ 5 years at screening, 
which included 15/29 patients in the burosumab group and 
20/32 patients in the conventional therapy group. Baseline 
assessments occurred at randomization for all participants 
after a 7-day washout period from prior conventional ther-
apy. Baseline characteristics for all participants (patients 
aged 1–12 years at screening) and those aged ≥ 5 years at 
screening are presented in Table 1. Overall, baseline charac-
teristics were similar between the two age cohorts; however, 
serum 1,25(OH)2D concentration was lower in the cohort 
aged ≥ 5 years than in the total patient group (mean ± SD: 
91 ± 36 vs 103 ± 43 pmol/L, respectively), particularly in the 
burosumab group (96 ± 38 vs 110 ± 48 pmol/L) (Table 1). 
Patients aged ≥ 5 years had received conventional therapy 
for a mean of 5.54 years.
PROMIS Pain Interference
Higher scores on the pain interference domain reflect pain 
having a greater impact on daily activities, with decreases in 
scores reflecting improvements in this domain. At baseline, 
the mean ± SD pain interference T-score was 53.1 ± 10.95 
for burosumab and 49.9 ± 12.02 for continued conventional 
therapy, broadly comparable to the mean of the calibration 
sample of 50 [14]. Eight of the 35 patients (23%) had pain 
interference scores ≥ 1 SD higher (worse) than the cali-
bration sample average (Fig. 1a). Pain interference score 
decreased from baseline in the burosumab group (least-
squares [LS] mean [SE] change: − 5.31 [1.705] at week 40 
and − 3.55 [1.873] at week 64), indicating reduced levels 
of pain interference, but changed little in the group who 
continued to receive conventional therapy (− 0.29 [1.539] 
at week 40 and − 1.29 [1.267] at week 64). The change in 
pain interference score exceeded the 3-point MID threshold 
in patients receiving burosumab at both weeks 40 and 64, 
consistent with a clinically meaningful reduction in pain 
interference for this group. The change from baseline in the 
group continuing conventional therapy was less than the 
3-point MID threshold. Burosumab was associated with a 
significantly greater change from baseline than conventional 
therapy at week 40 (between-group difference − 5.02, 95% 
CI − 9.29 to − 0.75; p = 0.0212) but not at week 64 (− 2.26, 
95% CI − 6.61 to + 2.09; p = 0.3091) (Fig. 2a). Descriptive 
item-level results at baseline and week 64 can be found in 
the appendix (Online Resource, Table 3).
PROMIS Physical Function Mobility
Higher scores on the PROMIS physical function mobility 
domain indicate less detriment (i.e., better physical function 
mobility), with increases in scores reflecting improvements 
in this domain. At baseline, the mean ± SD physical func-
tion mobility T-score was 45.2 ± 9.05 for burosumab and 
45.5 ± 9.86 for continued conventional therapy, similar to the 
mean of 50 of the calibration sample [14]. Twelve of the 35 
patients (34%) had impaired physical function indicated by 
physical function mobility scores ≥ 1 SD lower (worse) than 
the calibration sample average (Fig. 1b). Physical function 
mobility score increased numerically from baseline in the 
burosumab group (LS mean [SE]: + 2.78 [1.336] at week 
40 and + 2.82 [1.648] at week 64), indicating improved 
physical function mobility, but showed little change in 
the continued conventional therapy group (+ 0.10 [0.966] 
at week 40 and + 0.92 [0.962] at week 64). Neither group 
had achieved a meaningful change from baseline based on 
a 3-point MID. Differences between treatment groups were 
not statistically significant at either week 40 (+ 2.68, 95% 
CI − 0.52 to + 5.89; p = 0.1009) or week 64 (+ 1.90, 95% 
CI − 1.80 to + 5.59; p = 0.3145) (Fig. 2b). Descriptive item-
level results at baseline and week 64 can be found in the 
appendix (Online Resource, Table 3).
PROMIS Fatigue
Higher scores on the PROMIS fatigue domain reflect 
greater levels of fatigue, with decreases in scores reflecting 
improvements in this domain. At baseline, the mean ± SD 
fatigue T-score was 48.8 ± 9.60 for burosumab and 
47.0 ± 13.70 for continued conventional therapy, similar to 
the mean of 50 of the calibration sample [14]. Seven of the 
35 patients (20%) had fatigue scores at least 1 SD higher 
(worse) than the calibration sample average (Fig. 1c). 
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Fatigue scores decreased from baseline to weeks 40 and 
64 in burosumab-treated patients (LS mean [SE], − 4.29 
[1.709] at week 40 and − 3.65 [2.119] at week 64), reflect-
ing reduced levels of fatigue, but showed little change in 
those continuing to receive conventional therapy (LS mean 
[SE], − 1.05 [1.754] at week 40 and − 2.57 [1.547] at week 
64). Meaningful change from baseline was achieved for the 
burosumab group at weeks 40 and 64, based on a 3-point 
MID. There was no meaningful change for the conven-
tional therapy group at weeks 40 or 64. Between-group 
differences did not reach statistical significance at either 
week 40 (− 3.25, 95% CI − 7.86 to + 1.37; p = 0.1676) or 
week 64 (− 1.08, 95% CI − 6.21 to + 4.06; p = 0.6810) 
(Fig. 2c). Descriptive item-level results at baseline and 
Table 1  Patient demographic and baseline characteristics for participants ≥ 5 years at screening and for all patients (aged 1–12 years)
Max maximum, min minimum, ROW rest of world, RSS Rickets Severity Score, SD standard deviation, TmP/GFR tubular maximum for phos-
phate reabsorption per glomerular filtration rate




therapy (n = 20)
Total (n = 35) Burosumab 
(n = 29)
Conventional 
therapy (n = 32)
Total (n = 61)
Age, years,
Mean (SD) 8.6 (2.4) 8.4 (2.2) 8.5 (2.2) 5.8 (3.4) 6.3 (3.2) 6.3 (3.3)
Sex, n (%)
Boys 10 (66.7) 9 (45.0) 54.3) 13 (44.8) 14 (43.8) 27 (44.3)
Girls 5 (33.3) 11 (55.0) 16 (45.7) 16 (55.2) 18 (56.3) 34 (55.7)
Ethnic origin, n 
(%)
White 12 (80.0) 14 (70.0) 26 (74.3) 25 (86.2) 25 (78.1) 50 (82.0)
Asian 1 (6.7) 5 (25.0) 6 (17.1) 2 (6.9) 6 (18.8) 8 (13.1)
Other 1 (13.3) 1 (5.0) 3 (8.6) 2 (6.9) 1 (3.1) 3 (4.9)
Geographic region, 
n (%)
Japan 1 (6.7) 3 (15.0) 4 (11.4) 2 (6.9) 3 (9.4) 5 (8.2)
ROW 14(93.3) 17(85.0) 31 (88.6) 27 (93.1) 28 (90.6) 56 (91.8)
TmP/GFR, 
mmol/L
Mean (SD) 0.67 (0.12) 0.66 (0.11) 0.67 (0.11) 0.65 (0.11) 0.71 (0.12) 0.68 (0.12)
Height Z score
Mean (SD) − 2.4 (1.2) − 1.9 (0.8) − 2.1 (1.0) − 2.3 (1.2) − 2.1 (0.9) − 2.2 (1.0)
Median (min, max) − 2.0 (− 5.0, − 0.5) − 2.1 (− 3.1, − 0.1) − 2.0 (− 5.0, − 0.1) − 2.3 (− 3.1, − 1.5) − 2.1 (− 2.5, − 1.4) − 2.2 (− 5.0, − 0.1)
Weight, Z score
Mean (SD) − 1.0 (1.4) − 0.4 (0.8) − 0.9 (1.2) − 0.9 (1.2) − 0.6 (0.9) − 0.8 (1.0)













Mean (SD) 493.3 (146.4) 516.8 (168.1) 506.7 (157.3) 510.8 (124.9) 523.4 (154.4) 517.4 (140.2)
Total Thacher RSS
Mean (SD) 3.1 (0.8) 3.0 (0.9) 3.0 (0.8) 3.2 (1.0) 3.2 (1.1) 3.2 (1.1)
Median (min, max) 3.0 (2.0, 5.0) 3.0 (2.0, 4.5) 3.0 (2.0, 5.0) 3.0 (2.5, 4.0) 3.0 (2.5, 3.5) 3.0 (2.0, 6.5)
 R. Padidela et al.
1 3
week 64 can be found in the appendix (Online Resource, 
Table 3).
SF‑10 Health Survey for Children
The trial population had baseline scores below the 25th 
percentile for PHS-10 (mean [SD] score; 40.47 [13.14] 
total population, 40.03 [10.07] burosumab, 40.74 [15.30] 
conventional therapy) and below the 50th percentile for 
PSS-10 (mean [SD] score; 51.92 [9.42] total population, 
50.76 [9.65] burosumab, 52.79 [9.40] conventional therapy) 
(Fig. 3). Patients receiving burosumab showed significant 
improvements in LS mean (SE) PHS-10 scores from base-
line at both week 40 (+ 5.98 [1.79]; p = 0.0008) and week 
64 (+ 5.93 [1.88]; p = 0.0016) (Fig. 4a). By contrast, there 
were no statistically significant changes from baseline in 
the conventional therapy group at week 40 (+ 1.65 [2.17]) 
or week 64 (+ 0.44 [2.22]). The LS mean (SE) differences 
between the burosumab and continued conventional therapy 
groups did not meet statistical significance at either week 
40 (+ 4.33 [2.82]) or week 64 (+ 5.49 [2.91]). There were 
no statistically significant changes in LS mean (SE) PSS-10 
scores from baseline to weeks 40 or 64 for either burosumab 
(+ 1.53 [1.52] and + 0.94 [1.176], respectively) or contin-
ued conventional therapy (− 0.66 [1.38] and + 1.44 [1.21], 
respectively), with no significant differences between the 
two treatment groups (LS mean difference [SE]: + 2.19 
[2.10] at week 40; − 0.50 [2.12] at week 64) (Fig. 4b).
Faces Pain Scale—Revised
Most children in both treatment groups reported no pain 
at baseline, week 40, or week 64 according to the FPS-R. 
Median FPS-R scores were 0 at all time points for both 
groups, and there were no significant differences between 
groups (p = 0.8786).
Fig. 1  Baseline PROMIS (a) 
pain interference, (b) physi-
cal function mobility, and (c) 
fatigue scores for patients 
aged ≥ 5 years (n = 35). Data 
show standardized PROMIS 
T-scores; higher T-scores 
indicate more pain interference, 
better function mobility, and 
worse fatigue. Reference lines 
at ± 1 SD of the mean are based 
on a population mean of 50 and 
SD of 10. PROMIS Patient-
Reported Outcomes Measure-
ment Information System, SD 
standard deviation
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Subgroup Analyses
Treatment effect heterogeneity was assessed for the trial pop-
ulation in predefined subgroups: RSS: ≤ 2.5 (n = 22), > 2.5 
(n = 39); sex: male (n = 27), female (n = 34). Data by region 
(Japan [n = 5], rest of world [n = 56]) and PHEX status 
(clearly pathogenic PHEX variant [n = 55], or PHEX variants 
that were likely pathogenic/variant of unknown significance 
Fig. 2  Change from baseline in 
PROMIS (a) pain interference, 
(b) physical function mobil-
ity, and (c) fatigue scores for 
patients aged ≥ 5 years (n = 35). 
Data are expressed as LS mean 
(standard error). *p < 0.05 
for LS mean change at week 
40 (burosumab–conventional 
therapy). †Indicates the mean 
change is ≥ 3-point MID from 
baseline. LS least-squares, MID 




Fig. 3  Baseline SF-10 Health 
Survey for Children (a) PHS-10 
and (b) PSS-10 for patients 
aged ≥ 5 years (n = 35). P.25, 
P.50, and P.75 are the 25th, 
50th, and 75th percentiles from 
the general population. Higher 
global scores indicate better 
HRQoL. HRQoL health-related 
quality of life, PHS-10 physical 
health score, PSS-10 psychoso-
cial health score, SF-10 Short 
Form-10
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[n = 6]) were removed from this analysis because of the 
imbalance in patient numbers in these groups. No statis-
tically significant interactions (p < 0.05) were identified 
among the five PRO domains for the RSS and sex subgroup 
categories.
Discussion
Children with XLH whose PRO scores indicate pain inter-
ference, fatigue, physical function mobility impairment, and 
reduced HRQoL despite conventional therapy would benefit 
from a disease-modifying treatment that alleviates the dis-
order’s long-term physical and psychosocial complications 
[4]. Our phase 3 CL301 trial demonstrated that burosumab 
results in greater improvement in phosphorus homeostasis, 
growth, lower-extremity deformities, and healing of rickets 
in children with XLH compared with continuing conven-
tional therapy [9]. In the present analyses, we determined 
the impact of switching from conventional therapy to buro-
sumab treatment compared to continuing conventional ther-
apy on PROs of pain interference, physical function mobil-
ity, fatigue, and HRQoL.
Baseline PROMIS pain interference, physical function 
mobility, and fatigue scores were similar to the PROMIS 
calibration sample, which included 4,129 children primar-
ily from hospital-based general pediatric and subspecialty 
clinics. In this sample, 35% of children had consulted a cli-
nician for a chronic illness diagnosis or treatment within 
6 months, and 9% had two or more chronic illnesses [14]. 
Baseline PROMIS pain interference, physical function 
mobility, and fatigue scores were similar to those reported 
for other lifetime diseases that start in childhood, such as 
sickle cell disease, Crohn disease, juvenile arthritis, juvenile 
dermatomyositis, chronic kidney disease, or systemic lupus 
erythematosus [20–27].
Baseline SF-10 scores indicate impaired HRQoL in the 
present trial population, especially with regard to physical 
health, with lower baseline PHS-10 scores (mean score, 
40.03) than those seen in children with asthma, attention-
deficit hyperactivity disorder, depression, or learning dis-
abilities (mean range, 43.83–48.23) [12]. However, SF-10 
is a caregiver-completed questionnaire, which may under-
estimate the child’s health and well-being [28]. The FPS-R 
tool is validated to assess current pain, though it has not 
been psychometrically validated specifically in children with 
XLH. At all study visits, the XLH patients indicated no pain, 
suggesting that the FPS-R assessment of current pain at rest 
may not reliably assess the burden of pain severity in this 
population.
In patients who received burosumab, the decrease from 
baseline in pain interference was significantly greater than 
in those who continued conventional therapy, although only 
up to week 40. The improvement with burosumab was not 
fully sustained from week 40 to week 64 but did not return 
to baseline levels. The lack of a persistent benefit with buro-
sumab up to week 64 may be explained by small patient 
numbers and possible increased activity-related pain for 
patients who had received early benefit from burosumab. 
Furthermore, pain and its associated impact in XLH is com-
plex and multifactorial [1, 4], and expected improvements 
in bone health with burosumab may not be sufficient to fully 
address all aspects of pain syndrome over a short period of 
time.
Fig. 4  Changes from baseline 
to weeks 40 and 64 for SF-10 
Health Survey for Children (a) 
PHS-10 and (b) PSS-10 for all 
patients aged ≥ 5 years (n = 35). 
Data are expressed as LS 
mean ± standard error. *p < 0.01 
for change from baseline to 
week 64; **p < 0.001 for change 
from baseline to week 40. LS 
least-squares, PHS-10 physical 
health score, PSS-10 psychoso-
cial health score, SF-10 Short 
Form-10
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Improvements from baseline in the PROMIS physical 
function mobility and fatigue domains were also achieved 
with burosumab versus conventional therapy, although the 
differences between groups were not statistically significant. 
Patients receiving burosumab did have clinically meaning-
ful changes (based on 3-point MIDs) in two of the three 
PROMIS domains (pain interference and fatigue) by week 
40, which were maintained at week 64. Burosumab also sig-
nificantly improved the physical health domain (PHS-10) 
by approximately 10% at week 40, which was maintained 
at week 64. In patients receiving conventional therapy, 
changes in physical health from baseline were not seen; dif-
ferences between treatment groups did not reach statistical 
significance, although the trial was not powered to show 
differences in these endpoints. There were no statistically 
significant interactions among the five PRO domains for the 
predefined subgroup categories investigated (RSS and sex).
Improvements in PROs are reflected by mobility data 
from the 6-min walk test reported in the primary manuscript 
[9]. These data showed that patients randomized to buro-
sumab had significantly greater improvements from baseline 
in percent predicted distance walked over 6 min than those 
continuing to receive conventional therapy at week 64 (LS 
mean change from baseline 9% vs 2%; 95% CI 0.01–14.52; 
p = 0.0496) [9].
Improvements in pain interference, physical function 
mobility, fatigue, and HRQoL may be explained by the 
mechanism of action of burosumab. Burosumab addresses 
the deficiency of serum phosphate by directly binding to 
FGF23 and inhibiting its signaling, increasing tubular phos-
phate reabsorption, as well as increasing serum 1,25(OH)2D 
levels and increasing gastrointestinal phosphate absorption 
[29]. Increased serum phosphate levels result in improved 
bone mineralization [29], improved muscular function [30], 
and restoration of ATP synthesis [31–33], and thus ulti-
mately may manifest as improvements in patient-reported 
symptoms, function, and HRQoL.
In relation to PRO measurements, this trial has several 
limitations. Our trial was not powered to assess between-
group differences for secondary and exploratory outcomes, 
such as PROs, nor for subgroup analyses. For example, 
sample size was insufficient to explore whether higher 
phosphate concentration or rapidity of correction of alka-
line phosphatase reflected PRO measurements. Therefore, 
it remains unknown whether mid-range serum phosphate 
levels improve PROs to a greater extent than low-normal 
values. Children aged younger than 1 year or older than 
12 years were not recruited, and children younger than 
5 years did not complete PROs, precluding extrapolation of 
results to these age groups and limiting the sample size to 15 
patients in the burosumab group and 20 patients in the con-
ventional therapy group. Further, only those with RSS ≥ 2 
were enrolled in this trial; thus, the baseline PRO scores 
or the degree of expected improvement with treatment for 
those with lower RSS scores is not known. This trial only 
randomized treatment for 64 weeks, while XLH is a lifelong 
chronic disease. Further follow-up is warranted to determine 
longer-term effects on HRQoL and patient-reported pain 
interference, physical function mobility, and fatigue. Fur-
thermore, compared with the prior clinical standard of care, 
children on conventional treatment in this trial were perhaps 
more meticulously monitored and managed, because of the 
frequent visits and rigorous trial requirements. High levels 
of compliance and adherence to conventional treatment in 
clinical trial settings can result in greater improvements in 
outcomes with conventional therapy than that seen in routine 
standard of care [34–37].
In conclusion, in this phase 3 trial, changing from con-
ventional therapy to burosumab was associated with numeri-
cal increases in PROMIS physical function mobility, clini-
cally meaningful reductions in PROMIS pain interference 
and fatigue up to 64 weeks, and a statistically significant 
reduction in PROMIS pain interference up to 40 weeks. Sta-
tistically significant improvements in SF-10 PHS-10 were 
observed up to 64 weeks from baseline in children aged 
5–12 years with XLH.
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